Bilgrami ZR, Castro E, Agurto C, Liebenthal E, Ennis M, Baker JT, Scott I, Colton BL, Cho KIK, Li L, Tamayo Z, Henecks M, Rahimi Eichi H, Henry T, Addington J, Alameda LK, Arango C, Breitborde NJK, Broome MR, Cadenhead KS, Calkins ME, Chen EYH, Choi J, Conus P, Cornblatt BA, Ellman LM, Fusar-Poli P, Gaspar PA, Gerber C, Glenthøj LB, Horton LE, Hui C, Kambeitz J, Kambeitz-Ilankovic L, Keshavan MS, Kim SW, Koutsouleris N, Kwon JS, Langbein K, Mamah D, Diaz-Caneja CM, Mathalon DH, Mittal VA, Nordentoft M, Pearlson GD, Perez J, Perkins DO, Powers AR, Rogers J, Sabb FW, Schiffman J, Shah JL, Silverstein SM, Smesny S, Stone WS, Yassin W, Strauss GP, Thompson JL, Upthegrove R, Verma S, Wang J, Wolf DH, McGorry PD, Kahn RS, Kane JM, Anticevic A, Bearden CE, Dwyer D, Billah T, Bouix S, Pasternak O, Shenton ME, Woods SW, Nelson B, Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), Cecchi GA, Corcoran CM, Wolff PM. Collecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative. Schizophrenia (Heidelb). 2025 Oct 15; 11(1):125.
